Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma
暂无分享,去创建一个
I. Ellis | R. Blamey | C. Elston | M. Galea | W. Gullick | D. Pearson | D. Poller | J. Bell
[1] D. Barnes,et al. Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinomain situ , 1991, Breast Cancer Research and Treatment.
[2] T. Perren. c-erbB-2 oncogene as a prognostic marker in breast cancer. , 1991, British Journal of Cancer.
[3] A. Harris,et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.
[4] I. Ellis,et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. , 1991, British Journal of Cancer.
[5] J. Bártková,et al. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. , 1991, British Journal of Cancer.
[6] P. V. van Diest,et al. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer. , 1991, Laboratory investigation; a journal of technical methods and pathology.
[7] J. Bártková,et al. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. , 1990, Human pathology.
[8] R. Lupu,et al. Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. , 1990, Science.
[9] B. Angus,et al. c‐erbB‐2 oncoprotein expression in mammary and extramammary Paget's disease: an immunohistochemical study , 1990, Histopathology.
[10] J. Bacus,et al. HER-2/neu oncogene expression and proliferation in breast cancers. , 1990, The American journal of pathology.
[11] S. Ashley,et al. Immunohistochemical distribution of c‐erbB‐2 in in situ breast carcinoma—a detailed morphological analysis , 1990, The Journal of pathology.
[12] Joseph Schlessinger,et al. Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.
[13] J. Bacus,et al. HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. , 1990, Archives of pathology & laboratory medicine.
[14] A. Howell,et al. C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis. , 1990, British Journal of Cancer.
[15] G. Hortobagyi,et al. c-erbB-2 amplification in node-negative human breast cancer. , 1989, Cancer research.
[16] D. Barnes,et al. An immunohistochemical study of the presence of c‐erbB‐2 protein in Paget's disease of the nipple , 1989, Histopathology.
[17] D. Barnes. Breast cancer and a proto-oncogene. , 1989, BMJ.
[18] P. Quirke,et al. c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma. , 1989, British Journal of Cancer.
[19] J. Varley,et al. An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. , 1989, British Journal of Cancer.
[20] W. McGuire,et al. HER-2/neu oncogene protein and prognosis in breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Fernö,et al. HER2/neu AMPLIFICATION AND COMEDO TYPE BREAST CARCINOMA , 1989, The Lancet.
[22] S. Hirohashi,et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. , 1989, Cancer research.
[23] J. Varley,et al. An immunohistochemical and in situ hybridization study of c‐myc and c‐erbB‐2 expression in primary human breast carcinomas , 1989, The Journal of pathology.
[24] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[25] B Angus,et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.
[26] M. Lagios,et al. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence , 1989, Cancer.
[27] L. Skoog,et al. Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer. , 1989, European journal of cancer & clinical oncology.
[28] T. Powles,et al. Immunohistochemical distribution of c‐erbB‐2 in infiltrating and in situ breast cancer , 1988, International journal of cancer.
[29] M. J. van de Vijver,et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.
[30] D. Altman,et al. An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. , 1988, British Journal of Cancer.
[31] P. Leder,et al. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.
[32] J. Meyer,et al. Thymidine labeling index, flow cytometric S-phase measurement, and DNA index in human tumors. Comparisons and correlations. , 1988, American journal of clinical pathology.
[33] B. Groner,et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. , 1988, Cancer research.
[34] I. O. Ellis,et al. Confirmation of a prognostic index in primary breast cancer. , 1987, British Journal of Cancer.
[35] W. Gullick,et al. OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION , 1987, The Lancet.
[36] R. W. Baldwin,et al. Tumour aneuploidy, prognostic parameters and survival in primary breast cancer. , 1987, British Journal of Cancer.
[37] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[38] M. Yoshida,et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line , 1986, Molecular and cellular biology.
[39] M. Daidone,et al. Cell kinetics as a prognostic marker in node‐negative breast cancer , 1985, Cancer.
[40] I. Taylor,et al. Application of DNA flow cytometry to paraffin-embedded archival material for the study of aneuploidy and its clinical significance. , 1985, Cytometry.
[41] W. Göhde,et al. Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle , 1975, Radiation and environmental biophysics.
[42] A. Schauer,et al. c-erbB2 expression in correlation to other biological parameters of breast cancer , 2005, Journal of Cancer Research and Clinical Oncology.
[43] J. Meyer. Cell kinetics of histologic variants ofin situ breast carcinoma , 2005, Breast Cancer Research and Treatment.
[44] C R King,et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] D. Visscher,et al. Prognostic significance of morphological parameters and flow cytometric DNA analysis in carcinoma of the breast. , 1990, Pathology annual.
[46] W. Gullick. Expression of the c-erbB-2 proto-oncogene protein in human breast cancer. , 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[47] R. Cardiff. Cellular and molecular aspects of neoplastic progression in the mammary gland. , 1988, European journal of cancer & clinical oncology.
[48] A. Ullrich,et al. Growth factor receptor tyrosine kinases. , 1988, Annual review of biochemistry.
[49] W. J. Brammar,et al. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. , 1987, Oncogene.
[50] R. Silvestrini,et al. Cell proliferation and its relationship to clinical features and relapse in breast cancers. , 1981, Cancer.